HOME › Press Releases › In Vitro Diagnostics/IVD Market worth 78.74 Billion USD by 2021
In Vitro Diagnostics/IVD Market worth 78.74 Billion USD by 2021
The report "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to 2021", The global IVD market is valued at USD 60.22 Billion in 2016. This market is expected to grow at a CAGR of 5.5% during the forecast period (2016–2021) to reach USD 78.74 Billion by 2021.
Browse 181 market data tables and 51 figures spread through 306 pages and in-depth TOC on “In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to 2021”
Early buyers will receive 10% customization on reports.
The rising incidence of chronic lifestyle diseases, growth in the number of growth in the number of private diagnostic centers, and shift in focus from centralized laboratories to decentralized point-of-care testing are the key factors driving market growth. However, inadequate reimbursement and rising healthcare cost restraining the growth of this market.
In this report, the market is majorly segmented by products & services, technology, application, end user, and region. Based on products and services, the market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for largest share and it also be the fastest growing market during the forecast period. This is attributed to the rising number of IVD tests conducted and accessibility to a wide range of reagents.
On the basis of application, the market is segmented into diabetes, infectious diseases, oncology/cancer, cardiology, HIV/AIDS, autoimmune diseases, nephrology, drug testing/pharmacogenomics, and other applications. In 2015, the infectious diseases segment accounted for the largest share of the IVD market. The large share of this segment is attributed to the rise in the incidences of various infectious disorders such as tuberculosis (TB), hepatitis, and hospital-acquired infections which fueled the demand for IVD tests. Whereas, the oncology/cancer segment is expected to register the highest CAGR during the forecast period due to the growing incidence of cancer forms that stimulates the demand for early detection of the disease.
In 2015, North America accounted for the largest share of the IVD market, followed by Europe. Easy accessibility to technologically advanced products, presence of a large number of leading IVD manufacturers in the region are driving market growth in North America. Similarly, the rising prevalence of chronic lifestyle and genetic diseases, rising geriatric population, increasing acceptance of personalized medicine, and growing adoption of technologically advanced products are driving the growth of the North American IVD market. The Asia-Pacific region is expected to witness the highest growth in this market majorly due to improving healthcare infrastructure and growing economies in China and India. In addition, manufacturers are increasingly focusing on strengthening their presence in emerging APAC countries.
The global IVD market is highly competitive in nature, with the top five companies accounting for the major market share in 2015. Some key players in this market are Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Becton, Dickinson and Company (U.S.), Johnson and Johnson (U.S.), Qiagen N.V. (Germany), Ortho-Clinical Diagnostics, Inc. (U.S.), and Diasorin S.P.A. (Italy). These leading players have primarily focused on new product launches, acquisitions, agreements, collaboration, partnerships, and expansion for growth in the market.
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India